C3C
A neo-epitope fragment of type III collagen generated by cathepsin activity, enabling non-invasive assessment of interstitial matrix degradation and fibrotic remodeling in chronic diseases.
Key features and values
- Quantifies specific fragments of type III collagen produced by cathepsin-mediated cleavage.
- Reflects interstitial matrix degradation associated with fibrotic tissue remodeling.
- Provides a non-invasive measure of extracellular matrix turnover in chronic conditions.
- Supports monitoring of disease progression and response to anti-fibrotic therapies.
- Applicable in research on organ fibrosis, including kidney and liver diseases.
- Facilitates evaluation of interventions targeting extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The C3C biomarker assay measures specific neo-epitope fragments of type III collagen generated through cathepsin-mediated degradation, serving as an indicator of interstitial matrix remodeling in fibrotic diseases. This non-invasive assay provides insights into extracellular matrix turnover, supporting research and therapeutic development in conditions characterized by fibrosis. By quantifying collagen degradation products, the C3C assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of fibrotic tissue changes.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
